We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ASML:EURONEXT AMSTERDAMASML Holding NV Analysis

Data as of 2026-08-31 - not real-time

$1,696.16

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The moving-average structure behind ASML Holding N.V. is neutral at $1,696.16, with no clear ordering between short and long averages. Across the trailing 30 sessions it lost 2.9%. RSI sits at 43.4, which reads as neutral, and MACD momentum is bearish. Price has been bracketed by support at $1,582.00 and resistance at $1,896.35.
Multiples put this in overvalued territory: 57.1 times earnings against the sector's 35.7. Sell-side targets cluster 26.5% above the current quote. Revenue is growing at 21.3% on a 30.1% profit margin. The 0.54% dividend yield looks covered by current payout levels.
Risk comes out at 8 of a possible 10, a high reading. With 30-day volatility of 42.5%, a beta of 2.31 and a maximum drawdown of 22.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 2/10 conviction.

Top Market Events

ASML stock is being steered by heavy Q2 2026 share buybacks and a firm Q3 2026 outlook, while one inASML Holding NV ASML reports robust Q2 results, exceeding sales and margin expectations, while addressing challenges in...Semiconductor equipment manufacturer ASML ASML has announced an interim dividend of €1.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Trading above the 200-day average of 1464.04
  • MACD momentum is negative
  • 30-day volatility of 42.5%

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • P/E of 57.1 versus sector average of 35.7
  • Trading above the 200-day average of 1464.04
  • Analyst targets imply +26.5% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • P/E of 57.1 versus sector average of 35.7
  • Analyst targets imply +26.5% versus the current price
  • Profit margin of 30.1% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth21.30%
Profit Margin30.11%
P/E Ratio57.1
ROE53.94%
ROA16.45%
Debt/Equity9.09
P/B Ratio1423.2
Op. Cash Flow$11.5B
Free Cash Flow$8.4B
Industry P/E35.7

Technical Analysis

TrendNeutral
RSI43.4
Support$1,582.00
Resistance$1,896.35
MA 20$1,756.30
MA 50$1,768.21
MA 200$1,464.04
MACDBearish
VolumeStable
Fear & Greed Index94.25

Valuation

Fair Value$684.52
Target Price$2,145.38
Upside/Downside26.48%
GradeOvervalued
TypeGrowth
Dividend Yield0.54%

Risk Assessment

Beta2.31
Volatility42.45%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.